46,xy ovotesticular difference of sex development is a rare condition that affects how the reproductive organs form before birth. People with this condition may have a mix of testicular and ovarian tissue and genital features that are not clearly male or female. It is present from birth and care often continues across childhood and adulthood. Treatment focuses on individualized care, including hormone support, surgical options when needed, and ongoing psychosocial support. Not everyone will have the same experience, and with careful, person-centered care most people can live long and full lives.
Overview
46,xy ovotesticular difference of sex developmentSymptoms
Early signs of 46,xy ovotesticular difference of sex development include genitals that look between typical male and female, such as hypospadias or one undescended testicle. Later, puberty changes may be unexpected, and fertility can be reduced.
Outlook and prognosis
Most children with 46,XY ovotesticular difference of sex development grow and thrive, with care tailored to their body’s needs. Fertility varies, and regular checkups help track hormone levels, puberty, and future reproductive choices. Emotional support and experienced teams improve long‑term wellbeing.
Causes and risk factors
46,XY ovotesticular difference of sex development usually stems from genetic variants disrupting sex differentiation (for example, SRY, SOX9, NR5A1), or from mosaic/chimeric cell lines. Changes may be inherited or new. Family history or consanguinity raises risk; most cases are sporadic.
Genetic influences
Genetics play a central role in 46,XY ovotesticular difference of sex development. Variations in genes guiding gonadal formation or hormone signaling can lead to mixed ovarian and testicular tissue. Some cases are inherited, but many arise from new, sporadic variants.
Diagnosis
Doctors suspect 46,XY ovotesticular difference of sex development from newborn genital findings or puberty concerns. Confirmation uses hormone tests, ultrasound/MRI, genetic tests, and sometimes tissue biopsy; genetic diagnosis of 46,XY ovotesticular difference of sex development guides care.
Treatment and drugs
Treatment for 46,XY ovotesticular difference of sex development is individualized, guided by goals for health, future fertility, and gender identity. Care may include hormone support, careful monitoring, and, when helpful, surgery by experienced teams. Ongoing counseling and shared decision-making are central.
Symptoms
Many families first notice genital differences at birth or during the newborn exam. Early features of 46,xy ovotesticular difference of sex development may include a penis that’s smaller than expected, a urine opening lower on the penis, a larger clitoris, or testicles not felt in the scrotum. Features vary from person to person and can change over time. Other signs may appear later, such as mixed internal reproductive organs, unexpected changes at puberty, or issues with fertility.
The external genitals may not look typically male or female at birth. This can include a smaller penis, a larger clitoris, or scrotal/labial folds that look atypical. These differences are often picked up during the first exam.
One or both testicles may not be in the scrotum. A small lump may be felt in the groin instead, or a testicle may be absent on exam.
Some people with 46,xy ovotesticular difference of sex development have a combination of male- and female-typical internal reproductive organs. This can include testicular tissue on one side and ovarian tissue on the other, or both types within the same gonad.
If the urine opening sits lower on the penis (hypospadias), the stream may point downward or spray. This can make standing to urinate or toilet training more challenging until corrected.
How people usually first notice 46,xy ovotesticular difference of sex development?
Many families first notice something unusual at birth when the baby’s external genitals don’t look typically male or female, prompting the care team to check more closely. Doctors may then find both ovarian and testicular tissue on imaging or during surgery, and chromosome testing shows 46,XY, confirming a 46,XY ovotesticular difference of sex development. In some cases the first signs of 46,XY ovotesticular difference of sex development appear later in childhood with atypical puberty, such as slower testicular growth or unexpected breast development, leading to evaluation.
Types of 46,xy ovotesticular difference of sex development
46,XY ovotesticular difference of sex development is a genetic/congenital condition with a few recognized clinical variants. Variants are defined by where and how ovarian and testicular tissue are arranged, and by which organs form and function. These variants can lead to different hormone levels at birth and through puberty, which affects early symptoms of 46,XY ovotesticular DSD such as genital appearance, growth, and periods of hormone-related changes. Not everyone will experience every type.
Lateral variant
Ovarian tissue is on one side and testicular tissue on the other. External genital features and puberty changes often differ between the two sides. Fertility potential varies by side and may be asymmetric.
Bilateral variant
Both sides contain mixed ovarian–testicular (ovotesticular) tissue. Genital appearance is often mixed at birth, and hormone patterns can shift over time. The balance of symptoms can shift over time.
Unilateral variant
One side has ovotesticular tissue and the other side has either ovarian or testicular tissue alone. This can lead to more hormone influence from one type, shaping genital development and pubertal changes. Clinicians often describe them in these categories: lateral, bilateral, and unilateral.
What genetics can tell you about symptoms
Some people with 46,XY ovotesticular DSD have gene changes (often in SRY, SOX9, NR5A1, or WT1) that lead to mixed ovarian–testicular tissue, causing ambiguous genitalia at birth and later atypical puberty. These variants can also relate to undescended testes, reduced fertility, or cyclic bleeding.
Causes and risk factors
Most cases begin with changes in genes that guide early gonad development before birth. Genes set the stage, but environment and lifestyle often shape how the story unfolds. In 46,XY ovotesticular difference of sex development, the Y‑chromosome sex‑determining signal may be weak or altered, so both ovarian and testicular tissue can form. Some families have a history of sex development differences, but many cases arise as a new change with no known family risk. Lifestyle does not cause it, and environment mainly affects how and when early symptoms of 46,XY ovotesticular difference of sex development are noticed.
Environmental and biological risk factors
46,XY ovotesticular difference of sex development is uncommon. When discussing environmental and biological risk factors for 46,XY ovotesticular difference of sex development, most relate to very early fetal development when the gonads are forming. Small shifts in the timing or strength of hormone signals during this period can influence how ovarian and testicular tissue emerge. Researchers are still exploring how outside influences interact with our inner biology.
Between weeks 6 and 12 of pregnancy, hormone signals help guide whether early gonadal tissue becomes testicular or ovarian. Variations in the amount or timing of these signals can raise the chance of mixed gonadal tissue in 46,XY ovotesticular difference of sex development. This window is especially sensitive.
Early fetal testes depend on placental hormones for stimulation. Reduced or fluctuating support can lower androgen levels and influence how gonadal tissue forms. Evidence specific to 46,XY ovotesticular difference of sex development is limited.
Inside the developing gonad, local cell-to-cell cues steer tissue toward one pathway or the other. Disruptions in these cues can result in both ovarian and testicular tissue developing together. These are internal biological processes rather than external behaviors.
Exposure to certain pesticides, plasticizers, or industrial chemicals with hormone-like effects has been linked to differences in sex development in some human and animal studies. Evidence for a direct link to 46,XY ovotesticular difference of sex development is limited and not conclusive. Research is ongoing.
Genetic risk factors
The genetic causes of 46,XY ovotesticular difference of sex development are diverse. Many involve genes that steer early gonad development toward testis tissue; changes can shift that balance so both ovarian and testicular tissue form. Carrying a genetic change doesn’t guarantee the condition will appear. In some families, even detailed testing finds no single explanation.
SRY gene changes: Changes in the SRY gene on the Y chromosome can weaken the early testis signal. In some 46,XY ovotesticular difference of sex development cases, this lets ovarian-type tissue form alongside testicular tissue.
SOX9 pathway changes: Variants in SOX9 or its nearby control switches can lower this gene’s activity. Reduced activity can shift development so both ovarian and testicular tissue appear in 46,XY ovotesticular difference of sex development.
NR5A1 variants: NR5A1 helps the gonads and adrenal glands form. Changes in this gene are a recognized cause of 46,XY differences and have been reported in people with this condition.
NR0B1 duplication: An extra copy of NR0B1 (also called DAX1) on the X chromosome can counteract testis formation. In 46,XY individuals this dosage effect can result in partial sex reversal or ovotestes.
MAP3K1 variants: MAP3K1 controls signals that guide testis development. Certain inherited or new variants are linked to 46,XY gonadal differences, and some families include ovotesticular forms.
WT1 variants: WT1 is important for early kidney and gonad development. Altered WT1 can lead to a range of 46,XY differences, occasionally including ovotesticular patterns.
DMRT1 region loss: Loss or disruption of DMRT1 can impair testis development in 46,XY individuals. Rarely, this contributes to ovotesticular tissue in the same gonad.
DHH variants: Changes in DHH affect the support cells that help testis tissue mature. A minority of 46,XY cases develop ovotestes due to this pathway.
CBX2 variants: CBX2 helps set the balance between ovarian and testicular pathways. Rare variants have been reported in 46,XY ovotesticular difference of sex development.
Regulatory DNA changes: Alterations in noncoding DNA that turn sex development genes on or off at the right time can misdirect development. These changes are an emerging cause of 46,XY ovotesticular difference of sex development.
Tissue mosaicism: Some people have a genetic change in only part of their cells (mosaicism). Patchy loss of testis-determining signals can produce mixed ovarian and testicular tissue in 46,XY ovotesticular difference of sex development.
Inheritance patterns: Most cases are isolated, with no family history and a new (de novo) genetic change. When inherited, the pattern varies by gene and can be autosomal dominant, autosomal recessive, or X-linked.
Lifestyle risk factors
Lifestyle habits do not cause 46,xy ovotesticular difference of sex development, but they can influence symptoms, fertility potential, bone health, and recovery from procedures. Here’s how lifestyle affects 46,xy ovotesticular difference of sex development in day‑to‑day life. The choices below focus on modifiable behaviors and how they relate to hormones, reproductive tissue, and long‑term health. These are the lifestyle risk factors for 46,xy ovotesticular difference of sex development most clinicians discuss with patients and families.
Regular weight‑bearing and resistance exercise helps preserve bone density if sex‑steroid levels are low or after gonadal surgery. Lower body fat from activity can reduce aromatization of androgens to estrogens, stabilizing hormone‑related symptoms such as breast tenderness or irregular bleeding.
Adequate calcium, vitamin D, and protein support bone health when endogenous hormones are low or variable. Balanced meals that prevent excess weight gain can limit peripheral aromatization and lessen hormonal fluctuations that affect energy and mood.
Higher adiposity increases conversion of androgens to estrogens, which can influence breast development, bleeding patterns, and gynecomastia risk. Gradual weight loss, if needed, may ease these hormone‑sensitive symptoms and support cardiometabolic health.
Heavy alcohol and anabolic supplements can disrupt liver metabolism of sex steroids and destabilize hormone balance. Smoking increases surgical and wound‑healing complications and accelerates bone loss, which is concerning if sex‑steroid levels are low.
Risk prevention
For 46,XY ovotesticular difference of sex development, prevention focuses on avoiding complications and supporting healthy growth rather than stopping the condition itself. Regular follow-up with a specialized team can lower risks linked to hormone changes, tumors in gonadal tissue, and surgical issues. Different people need different prevention strategies—there’s no single formula. Early conversations about care goals help families and clinicians make steady, informed choices over time.
Ongoing visits with a DSD-experienced team help catch issues early and guide age-appropriate care. This supports steady growth, development, and well-being over time.
Some gonadal tissue can develop tumors, so scheduled exams and imaging may be advised. Early detection offers simpler treatments and better outcomes.
Regular blood tests and clinical checks track hormone levels that support growth, puberty, bone health, and energy. Adjusting hormone therapy when needed can prevent symptoms from low or high hormone levels.
A personalized plan helps time and dose any hormone support if puberty is delayed or uneven. This can reduce mood changes, growth problems, and period or testicular discomfort.
Transmission
46,xy ovotesticular difference of sex development is not contagious; it cannot be caught or passed between people. It starts before birth, most often because of changes in genes or early gonadal development.
Many cases have no family history and result from a new genetic change. When a gene change is found, how 46,xy ovotesticular difference of sex development is inherited can vary, so the chance of it happening again depends on the specific change and whether a parent carries it. Genetic counseling can help explain the genetic transmission of 46,xy ovotesticular difference of sex development and discuss future pregnancy planning.
When to test your genes
Test your genes if you or your child have genital features that don’t clearly fit typical male or female patterns, mismatched chromosomes and anatomy on prior tests, delayed or absent puberty, or unexpected hormone levels. Genetic testing also helps before major decisions like gonad surgery or fertility planning. Seek testing sooner if there’s a family history of differences in sex development.
Diagnosis
Day to day, first clues often appear at birth when the genital area looks different than expected, or later when puberty changes don’t follow a usual pattern. Getting a diagnosis is often a turning point toward answers and support. For 46,XY ovotesticular difference of sex development, doctors combine what they see on exam with focused hormone tests, imaging, and sometimes minor surgery to look at tissue. The genetic diagnosis of 46,XY ovotesticular difference of sex development usually involves chromosome testing and, when helpful, broader genetic tests to clarify the cause and guide care.
Doctors look for features like genital ambiguity, undescended testes, or differences in the opening of the urethra. They check for asymmetry and feel for gonads in the groin or abdomen. These findings help set the testing plan.
Blood tests check levels of testosterone, AMH, LH, and FSH to see how the gonads are working. A short stimulation test may be used to see how much testosterone the body can make. Patterns in results point toward specific causes.
A chromosome study confirms the 46,XY pattern. This helps distinguish among differences of sex development with similar outward features. It also guides which follow-up tests make sense.
Targeted tests look for changes in genes involved in gonad development. Results can explain why both ovarian and testicular tissue formed. They also inform recurrence risk and family counseling.
Stages of 46,xy ovotesticular difference of sex development
46,xy ovotesticular difference of sex development does not have defined progression stages. It’s a variation present from birth, and while bodies and hormone patterns can change with growth, it doesn’t follow a step-by-step worsening; features may be noticed in the newborn period or around puberty. Different tests may be suggested to help confirm what’s going on, such as a physical exam, blood tests for hormones, ultrasound, and chromosome and gene testing; early symptoms of 46,xy ovotesticular difference of sex development may include genital differences seen at birth or unexpected changes at puberty. Ongoing care usually means periodic check-ins with a multidisciplinary team to monitor growth, puberty, fertility considerations, and to discuss individualized support and tumor-risk screening when relevant.
Outlook and prognosis
Looking at the long-term picture can be helpful. Many people with 46,XY ovotesticular difference of sex development (DSD) grow up to live active, full lives, though health needs vary by the mix of ovarian and testicular tissue and how hormones shift over time. Early care can make a real difference, especially when a coordinated team follows growth, puberty, and hormone levels and tailors support to the person’s goals.
Fertility is variable. Some people with 46,XY ovotesticular DSD can produce sperm or eggs, but many will need assisted options or may choose paths like adoption; discussing early symptoms of 46,XY ovotesticular DSD such as atypical puberty or hormone fluctuations can guide timely evaluation. The lifetime risk of a gonadal tumor is higher than average when atypical gonadal tissue is present, so doctors often recommend regular imaging and blood tests, and sometimes preventive surgery for specific tissues at higher risk. With consistent monitoring and appropriate hormone care, many people maintain stable health and energy over the long term. Mortality related directly to 46,XY ovotesticular DSD is low when medical care is accessible, but outcomes are best with ongoing follow-up.
The outlook is not the same for everyone, but personalized plans that include hormone management, sexual and reproductive health counseling, and mental health support tend to improve quality of life. Social and emotional wellbeing matter just as much as lab results; having clinicians who respect privacy and involve the person in decision-making is linked to better satisfaction in adulthood. Talk with your doctor about what your personal outlook might look like, including plans for surveillance, fertility options, and steps to take if new symptoms appear.
Long-term effects
46,xy ovotesticular difference of sex development can have a wide range of long-term effects, shaped by how the gonads function and how the body responds to hormones. Long-term effects vary widely, and the picture often becomes clearer over time. Early symptoms of 46,xy ovotesticular difference of sex development do not always predict later puberty, fertility, or tumor risk. For many, the outlook becomes more defined across childhood and adolescence as development unfolds.
Puberty may start earlier, later, or proceed unevenly depending on how testicular and ovarian tissue work. Some develop typical male or female patterns, while others have mixed changes.
Fertility ranges from limited to possible, and it differs between individuals with 46,xy ovotesticular difference of sex development. Some may produce sperm or have eggs and a uterus that can support pregnancy, while others may not.
Lifelong hormone patterns can be stable or fluctuate, influenced by how much active gonadal tissue is present. This can affect energy, body composition, body hair, and libido.
Dysgenetic or mixed gonadal tissue can carry a higher chance of tumors over time, particularly with Y‑chromosome material. In 46,xy ovotesticular difference of sex development, this risk is an important long-term consideration.
How is it to live with 46,xy ovotesticular difference of sex development?
Living with 46,XY ovotesticular difference of sex development can mean navigating medical checkups, lab tests, and sometimes surgeries, alongside questions about gender identity, fertility, and body changes over time. Many balance routine health care—like hormone monitoring and cancer screening of any remaining gonadal tissue—with the very human work of building confidence, intimacy, and trust in relationships. Family, partners, and close friends are often part of the journey; with good communication and supportive clinicians, they can learn how to show up helpfully rather than anxiously. For many, connecting with knowledgeable providers and peer communities turns uncertainty into a clearer path forward.
Treatment and drugs
Treatment for 46,XY ovotesticular difference of sex development focuses on safety, hormone balance, future fertility options, and supporting the person and family in gender development over time. Care is usually coordinated by a specialized team—endocrinology, urology, gynecology, genetics, psychology—so decisions about surgery or hormones are made thoughtfully and not rushed. Supportive care can make a real difference in how you feel day to day, including counseling, peer support, and guidance on navigating school, sports, and later reproductive planning. Medical treatments may include careful monitoring without surgery, hormone therapy to address low or high levels of testosterone or estrogen, and, in selected cases, surgery to remove tissue with a higher tumor risk or to help with urinary or genital function; timing is individualized, and many procedures can be delayed until the person can participate in decisions. Regular follow-up includes tumor surveillance of gonadal tissue, bone and metabolic health checks, and revisiting goals as needs change through childhood, puberty, and adulthood.
Non-drug treatment
Living with 46,xy ovotesticular difference of sex development is about steady, thoughtful care that supports health, development, and family well‑being over time. Non-drug treatments often lay the foundation for day-to-day comfort, safety, and informed choices. Early symptoms of 46,xy ovotesticular difference of sex development can show up at birth as differences in genital appearance, so early team-based care matters. Plans are personalized and may change as a child grows and their needs and preferences become clearer.
A coordinated DSD team (endocrinology, urology/gynecology, genetics, psychology, nursing) helps map out the safest, most thoughtful plan. This reduces rushed decisions and keeps care consistent over time.
A genetics professional explains test results in plain language and what they may mean for health and family planning. They also discuss inheritance and answer questions about future pregnancies.
Counseling for the child and family can ease stress, support resilience, and help with body image and peer issues. Supportive therapies can also help families navigate complex choices without feeling alone.
Ongoing, age-appropriate conversations help families notice how identity and comfort evolve over time. Options like social transition are considered carefully and paced to the child’s needs.
Your genes may have an impact on how drugs work for you
Medicines used in 46,XY ovotesticular difference of sex development can work differently depending on genes that shape hormone production, receptor sensitivity, and how the body activates or clears drugs. Because of this, clinicians often individualize dosing and monitor response closely.
Pharmacological treatments
Pharmacological treatment for 46,xy ovotesticular difference of sex development focuses on matching hormone levels and body changes to a person’s goals, such as how puberty unfolds, managing periods, and easing features that feel out of sync. When early symptoms of 46,xy ovotesticular difference of sex development include early or unexpected puberty changes, medicines can help pause or guide development in a reversible way. Choices are individualized, and plans can change as needs evolve over time. Not everyone responds to the same medication in the same way.
Testosterone cypionate or enanthate injections, or transdermal gel, can induce and maintain masculinizing puberty. It supports muscle and bone strength and deepens the voice. Acne, mood shifts, and red blood cell changes may occur and need monitoring.
Oral or transdermal 17β‑estradiol can induce breast development and support feminine puberty. If a uterus is present, a progestin is often added to protect the uterine lining.
Medroxyprogesterone acetate or norethindrone acetate can suppress or regulate menstrual bleeding. This may ease cramps and reduce dysphoria tied to bleeding. Dosing can be cyclic or continuous based on goals.
Ethinyl estradiol/levonorgestrel or similar combined oral contraceptives can control cycles and reduce bleeding. They also provide contraception if needed. Some take them continuously to stop periods.
Genetic influences
In 46,XY ovotesticular difference of sex development, genes that steer early gonad formation can influence whether ovarian and testicular tissue develop side by side. Most genetic causes of 46,XY ovotesticular difference of sex development seem to arise sporadically from new genetic changes or alterations in the switches that control those genes, rather than from a pattern that clearly runs in a family. Having a gene change doesn’t always mean you will develop the condition. Small changes can act like a dimmer switch—lowering the strength of the testis pathway or keeping ovary pathways active—so an ovotestis can form even with a typical 46,XY chromosome pattern. Sometimes chromosomal differences or a mix of chromosome patterns in different cells can contribute to ovotesticular DSD, but these are less common in those confirmed to be 46,XY. Genetic testing may find a cause in some people with 46,XY ovotesticular DSD, while others won’t have a single identifiable reason, and results can guide counseling about recurrence risk and care planning.
Is 46,xy ovotesticular difference of sex development genetic?
Genetics play a central role in 46,XY ovotesticular difference of sex development. Variations in genes guiding gonadal formation or hormone signaling can lead to mixed ovarian and testicular tissue. Some cases are inherited, but many arise from new, sporadic variants.
Pharmacogenetics—how genetics influence drug effects
In 46,xy ovotesticular difference of sex development, genetic findings can guide which hormones are likely to help and the dose that feels right. Differences in hormone receptors and in liver enzymes that make or break down hormones can change how well testosterone or estrogen works and what side effects show up. Genetic testing can sometimes identify how your body processes certain hormones or common medicines, helping your care team tailor treatment and lower the chance of side effects. After surgery, pain relievers like codeine or tramadol may be less effective or too strong in some people because of inherited differences in drug‑processing enzymes, so alternatives are often chosen if needed. If estrogen is part of care, known inherited clotting risks can influence safety and monitoring plans, and your history may guide whether testing is useful before starting. Genes are only one factor; age, other health conditions, and how a medicine is taken (pill, patch, gel) also shape response, but using pharmacogenetics can shorten trial‑and‑error in choosing medication options for 46,xy ovotesticular difference of sex development.
Interactions with other conditions
People with 46,xy ovotesticular difference of sex development may find that other health issues shape their care plan and risks over time. For example, undescended gonadal tissue or prior hernias can raise the chance of gonadal tumors, so urology and endocrine teams often coordinate extra checks and imaging. Mental health conditions such as anxiety or depression can occur alongside medical stressors and body changes, and getting support early can improve coping, sleep, and treatment follow-through. Urinary tract infections may be more likely after certain surgeries or with genital or urinary differences, and issues like diabetes can make infections harder to clear, so prevention and swift treatment matter. Long-term low sex hormone levels can reduce bone strength; if someone also has vitamin D deficiency or limited mobility, the combined effect can increase fracture risk, making bone health monitoring important. When discussing early symptoms of 46,xy ovotesticular difference of sex development with your care team, it’s also worth reviewing any other diagnoses, because they can affect screening schedules and decisions about estrogen or testosterone therapy; these medicines carry specific considerations, such as blood clot risk with estrogen and effects on blood pressure or cholesterol with testosterone. Talk with your doctor about how your conditions may influence each other.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns that puzzled them: a baby assigned male at birth who later, during childhood or adolescence, showed features that didn’t fit neatly into male or female categories. Midwives and physicians recorded these stories in brief notes, describing mixed or changing development without the tools to look inside the body. Some accounts mentioned groin swellings thought to be undescended testes, while others noted bleeding in adolescence. The language was inconsistent, and care differed widely depending on place and era.
First described in the medical literature as “true hermaphroditism,” early reports focused on what doctors could see during examinations or surgery. Over time, descriptions became more precise as pathologists found that some individuals had both ovarian and testicular tissue. As medical science evolved, the term shifted to “ovotesticular” to reflect that tissue finding, and later to “difference of sex development” to emphasize biology rather than judgment. 46,XY ovotesticular difference of sex development falls within this broader group, but it took decades to recognize that some people with this condition have a typical male chromosome pattern (46,XY) while others have different patterns.
In the mid-20th century, new imaging and hormone testing helped clinicians move beyond surface features. Biopsies confirmed the presence of ovotestes in some, and hormone profiles hinted at how the body was signaling during fetal life and puberty. With each decade, teams became more multidisciplinary, bringing together endocrinology, urology, gynecology, pathology, and psychology to guide decisions that used to be made quickly and sometimes without long-term follow-up.
Advances in genetics clarified why 46,XY ovotesticular difference of sex development occurs for some people but not others. Researchers identified changes in genes that act like dimmer switches for gonadal development, showing how small shifts early in pregnancy can lead to mixed ovarian and testicular tissue. These findings also explained the variability in early symptoms of 46,xy ovotesticular difference of sex development—from genital appearance at birth to changes that only emerge at puberty.
In recent decades, awareness has grown around the importance of careful, individualized care and shared decision-making. Historical differences highlight why current guidance emphasizes thorough evaluation, time for families to ask questions, and attention to future fertility and hormone health. Looking back helps explain why the terminology evolved and why today’s approach focuses on health, function, and personal well-being rather than fitting bodies into narrow categories.